The University of Wisconsin-Madison and the University of Massachusetts-Amherst are conducting a research study to learn about links between learning and language in Fragile X syndrome.
About the Study
Who can participate?
Males with fragile X syndrome ages 9-16 years may be eligible to participate.
What will happen in the study?
If the individual qualifies and decides to be in this research study, they will come to UW-Madison (Wisconsin) or UMass-Amherst (Massachusetts) for a total of two site visits, two years apart.
The following is a list of some of the study procedures that will happen during the study:
- Language assessments
- Cognitive testing
- Questionnaires
What are the good things that can happen from this research?
There will be no immediate benefits to participating in this research.
However, participation will provide the fragile X community and researchers with a better understanding of how language and learning are linked over time. This information could help with future interventions.
Participants will be compensated for their time and travel.
What are the bad things that can happen from this research?
A potential risk of participation includes the potential for a breach of confidentiality, although the study involves protections to minimize such risks. In addition, participants may become embarrassed or anxious when they are asked study questions or are completing study tasks.
There may be other risks that we do not know about yet.
Will I or my child be paid to complete this study?
Participants receive $75 per visit, totaling $150.
Travel reimbursement is available for eligible families.
Interested in Participating?
Our Most Recent Opportunities
Study: Language Study for Children and Adolescents with Fragile X syndrome
Researchers at the University of Wisconsin-Madison and the University of Massachusetts-Amherst are conducting a study to learn about links between learning and language in Fragile X syndrome.
Survey: Fragile X Nutrition Survey
The University of Wisconsin-Madison is conducting a survey to learn about associations between infant feeding and neurodevelopment in children with Fragile X syndrome.
Clinical Trial: Phase 2B/3 Studies of BPN14770 in Fragile X syndrome
Tetra Therapeutics is conducting a two randomized, placebo-controlled studies of BPN14770/zatolmilast to learn about the experimental drug’s safety and efficacy for males ages 12-45.
IMPACT-FXS: Investigating Multiple Pathways And Combined Treatments for FXS
Healx is conducting a Phase 2, placebo-controlled study in adolescent and adult males with fragile X syndrome (FXS). The purpose of this study is to confirm whether Healx's drug candidates are safe and work as intended to reduce symptoms of FXS.
Survey: Developing a Gold Standard for Tracking Adult Functional Outcomes in Developmental Disabilities (AFS Study)
University of Pittsburgh is conducting this research to develop the Adult Functioning Scale (AFS), a new survey being designed to capture outcomes in the areas of social functioning, employment, independence, and satisfaction for individuals with various developmental disorders.
Study: Aging in Toolbox
Researchers around the country are conducting a study to better understand cognitive profiles in adults with intellectual disability. This study is an extension of the ongoing Toolbox Study, which is aimed to optimize cognitive assessment tools for children and young adults with intellectual disabilities.